PATENT CLAIM ANALYSIS

Application Number: 15907117
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["540", "461000"]

Abstract:
The present invention describes a new crystalline form of rifaximin, characterized in that it is a solvated form of rifaximin called rifaximin τ The invention also describes a process for the preparation of rifaximin τ, a pharmaceutical composition comprising said rifaximin form, and its use for treating inflammations and infections.

Claim (Index 9):
A pharmaceutical composition comprising an effective amount of the diethylene glycol monoethyl ether solvate rifaximin \u03c4 together with pharmaceutically acceptable excipients.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 88.0
- Lexical Diversity: 1.54286
- Patent Class: 540.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15310436', '13935331', '11814628', '13582676', '14261337']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.686567720468311
- 35 USC 102 Novelty (BERT): 0.5794060162734513
- Combined Prediction Score: 0.6758515500488251
- Mean Citation Score: 234.718832
- Max Citation Score: 411.19748
- Similarity Product: 255.386057523818

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test